A genetic predisposition to the development of neuroleptic malignant syndrome (NMS) has been suggested by clinical studies. Although the molecular basis of NMS is unclear, a dopaminergic blockade mechanism has been considered the main cause. We therefore investigated the association between NMS and three functional polymorphisms of the dopamine D 2 receptor (DRD 2 ) gene: TaqI A, À141C Ins/Del, and Ser311Cys. Subjects included 32 Japanese patients, previously diagnosed with NMS, and 132 schizophrenic patients treated with neuroleptics without occurrence of NMS. Polymerase chain reaction and restriction fragment length polymorphism analyses were performed to determine each genotype. We found significant differences in genotypic and allelic frequencies of the -141C Ins/Del polymorphism between patients with and without NMS. The À141C Del allele was significantly more frequent in the NMS group (23.4 vs 11.7%, P¼0.026). Similarly, the proportion of À141C Del allele carriers was significantly higher in the NMS group (40.6 vs 20.5%, P¼0.022). No significant differences between the two groups were seen for allelic and genotypic frequencies of the TaqI A and Ser311Cys polymorphisms. This result suggests that the À141C Ins/Del polymorphism is likely to predispose toward the development of NMS, probably together with other unidentified factors.
Introduction
Neuroleptic malignant syndrome (NMS) is a severe adverse effect of psychotropic drugs characterized by hyperthermia, extrapyramidal signs, altered consciousness, and autonomic dysfunction. In addition to acquired physical risk factors, previous case reports including descriptions of familial occurrence have suggested a genetic predisposition toward NMS, 1,2 and a molecular basis for NMS has been pursued.
A dopaminergic blockade mechanism has been considered to play a major role in NMS because most neuroleptics with a blocking effect at the dopamine D 2 receptor (DRD 2 ) can cause NMS, while discontinuation of neuroleptic medication usually improves symptoms of NMS. Therefore, central dopaminergic dysfunction, especially at DRD 2 , is believed to contribute to the development of NMS. Accordingly, several genetic studies with respect to DRD 2 have been performed.
A number of functional polymorphisms have been identified in the DRD 2 gene to date. Among these, the Ser311Cys polymorphism in exon 7 was suggested to affect the interaction between DRD 2 and its G protein. 3 The À141C Ins/Del polymorphism situated in the promoter region was suggested to affect promoter activity by an expression study using human cells. 4 The Del allele was found to increase the DRD 2 density in the striatum of the human brain, while the TaqI A1 allele in the 3 0 -untranslated region was demonstrated to reduce receptor density. 5, 6 Recent studies have shown a possible association of these polymorphisms with interindividual differences in both early therapeutic effects and adverse effects of neuroleptics. [7] [8] [9] In terms of NMS, Suzuki et al 10 suggested a possible association between NMS in Japanese patients and the TaqI A polymorphism, but we could not replicate their result in larger patient samples.
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In the present study, we performed systematic screening for these DRD 2 polymorphisms and assessed genetic associations with the occurrence of NMS in Japanese patients.
Methods

Subjects
We studied 32 patients (17 men and 15 women; mean age, 49.2 years; SD, 18.2) who had experienced NMS (27 patients with schizophrenia, one with schizoaffective disorder, three with mood disorder, and one with a psychotic disorder followed after viral encephalitis). Our control subjects were 132 patients with schizophrenia who had taken neuroleptics for more than 1 year and had never developed NMS (70 men and 62 women; mean age, 46.8 years; SD, 15.7). Psychiatric diagnoses were made according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). NMS was diagnosed retrospectively according to the criteria of Pope et al, 12 with all NMS cases confirmed as definite by these criteria. All subjects were Japanese, and no subject had a diagnosis of substance abuse. This study was approved by the Ethics Committee of Yokohama City University School of Medicine, and written informed consent was obtained from all subjects.
Genetic analysis
Genomic DNA was extracted from peripheral white blood cells from all patients using standard techniques. Polymerase chain reaction and restriction fragment length polymorphism analyses were performed to determine TaqI A genotypes according to Grandy et al;
13 À141C Ins/Del genotypes according to Hori et al; 14 and Ser311Cys genotypes according to Arinami et al, 15 respectively. Genetic analyses were performed by an investigator kept unaware of which subjects had developed NMS.
Statistical analysis
Statistical analyses were performed using w 2 tests with the Monte Carlo method or Fisher's exact test to determine the presence of allelic and/or genotypic associations. In addition, the logistic regression analysis was performed to evaluate simultaneously the possible associations between NMS and independent variables (DRD 2 genotypes, gender, and age). For the regression model, the allelic effect was assumed to be additive, that is, scores of 0, 1, and 2 were assigned for genotype wild homozygotes, heterozygotes, and mutant homozygotes of each mutation, respectively.
The differences in demographic characteristics between NMS patients with and without polymorphisms were evaluated by Fisher's exact test for categorical variables (gender distribution and NMS recurrence) and the Mann-Whitney U-test for continuous variables (age of onset of NMS, duration of illness, and neuroleptic dose). The neuroleptic dose before NMS onset was calculated in terms of chlorpromazine equivalents. 16, 17 The presence of Hardy-Weinberg equilibrium was determined using the w 2 test. These analyses were performed using SPSS 10.0 for Windows (SPSS Japan, Tokyo). Pairwise linkage disequilibrium and estimated haplotypes were analyzed using ARLEQUIN 2.000. 18 Table 3 shows the demographic characteristics of NMS patients with and without polymorphisms at the A1, Del, and Cys alleles. In any polymorphisms, no significant differences were noted for gender, age at NMS onset, duration of psychiatric illness, neuroleptic dose at NMS onset, or proportion of patients with recurrence of NMS among A1, Del, or Cys carriers and noncarriers.
Results
Haplotype analysis revealed a marginally significant linkage disequilibrium between the TaqI 
Discussion
A dopaminergic blockade mechanism in the central nervous system is presumed to be the main cause of NMS, and this hypothesis has been supported by several reports. Nishijima et al 19 showed that the cerebrospinal fluid concentration of homovanilic acid (HVA), a metabolite of dopamine, was low in the active phase of NMS and also after recovery. Jauss et al 20 demonstrated using single photon emission computed tomography (SPECT) that DRD 2 in the basal ganglia had been completely occupied during the acute state of NMS. Naturally, the DRD 2 gene is of great interest in investigating the vulnerability to NMS. Furthermore, recent pharmacogenetic studies have shown that the DRD 2 gene polymorphisms confer interindividual differences in responses to neuroleptic treatment. In the present study, we performed systematic screening for three functional DRD 2 polymorphisms, and assessed the relationship between NMS and these polymorphisms. As a result, we found significant differences in genotypic and allelic frequencies of the -141C Ins/Del polymorphism between patients with and without NMS. Frequencies of the À141C Del allele and Del carriers were significantly higher in the NMS group. These examined the transient expression of luciferase enzymatic activity for reporter plasmids containing the Del or Ins allele, noting less efficient expression with the Del allele. These various observations suggested that this polymorphism could be an important factor affecting clinical phenotypes concerning the dopaminergic system. Furthermore, the unreplicated result concerning the human striatal DRD 2 density remains of great interest. Relatively decreased DRD 2 expression might predispose NMS occurrence. However, the results of receptor density studies in vivo are inconsistent so far, and we could not elucidate the pathogenetic mechanism of NMS in our present study.
In the present study, no significant differences in allelic or genotypic frequencies of the TaqI A or Ser311Cys polymorphisms were seen between the two groups. In previous studies, Otani and colleagues The number of patients with recurrence of NMS/all NMS patients with or without the lower alleles. reported an association between the A1 allele of the TaqI A polymorphism and NMS, 10, 25 whereas the -141C Ins/Del polymorphism was not associated with NMS. 25 We suspect that a difference in a sample size can explain the discrepancy in the results between the previous and present studies. While we examined 32 NMS cases, the previous investigators compared 15-17 NMS cases with 138-163 control cases, which might have influenced the results. On the other hand, we found a significant difference in a haplotype distribution between patients with and without NMS. Especially, a frequency of A2-Del-Ser haplotype was estimated to be significantly higher in NMS. Combinations of these three polymorphisms could be a marker for the prediction of NMS, and further haplotype studies based on larger samples are needed.
In terms of the demographic profiles of NMS patients, we noted no significant differences in the clinical background, including the neuroleptic dose between NMS patients with and without the À141C Del allele. Although, in general, the incidence of NMS is fairly low, some patients in our study had recurrent NMS. We know that some NMS patients experience recurrence even without known acquired physical risk factors, and we hypothesized that at least some recurrences would involve constitutional factors regulated by genetics. We could not confirm this hypothesis, finding no significant differences in genotypic distribution in patients with NMS recurrence. However, the numbers of cases with NMS recurrence appeared to be too small to resolve the issue.
In conclusion, our findings suggest that the À141C Ins/Del polymorphism is likely to affect vulnerability toward development of NMS. However, the sample size for our NMS patients was relatively small, and further large case-control studies will be needed to confirm population frequencies and the status of the Del allele with respect to NMS. In addition, we believe that by itself the Del allele cannot explain all NMS occurrences. Other genetic association studies concerning NMS have been performed from both pharmacokinetic and pharmacodynamic points of view, 26, 27 and additional genetic studies considering effects of factors in combination are needed to elucidate the nature of genetic predisposition toward NMS.
